pd1in17

PD-1-IN-17 is an inhibitor of programmed cell death-1 (PD-1). PD-1-IN-17 inhibits 92% splenocyte proliferation at 100 nM.

PD-1-IN-22 is a potent inhibitor of the programmed cell death-1 (PD-1) programmed cell death-ligand 1 (PD-L1) interaction, with an IC50 of 92.3 nM.

ACTH (1-17) acetate is a potent agonist at the human melanocortin 1 (MC1) receptor with high affinity(Ki = 0.21 nM).

PD-1 PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1 PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model.

RMP1-14 is an IgG1-like immunoglobulin and anti-Mouse PD-1 antibody that blocks PD-1/PD-L1 signaling.

PD-1-IN-17 TFA is a inhibitor of programmed cell death-1 (PD-1) .

PD-1-IN-25 (compound 43) serves as a powerful inhibitor of the PD-1 PD-L1 interaction, boasting an impressive IC50 of 10.2 nM, as measured in the HTRF assay. By impeding PD-1 PD-L1 cellular signaling, PD-1-IN-25 facilitates the activation of CD8+ T cells. Furthermore, it has been shown to delay tumor growth [1].

PD-1 PD-L1-IN-32 (compound A56) is a potent inhibitor of PD-1 PD-L1 with an IC50 value of 2.4 nM, demonstrating significant anticancer activity. It effectively suppresses tumor growth in the hPD-L1 MC38 humanized mouse model and exhibits negligible toxicity to the normal functions of the mice [1].

PD-L1-IN-1, a powerful PD-L1 inhibitor, demonstrated an IC50 of 115 nM. By forming a robust bond with the PD-L1 protein, PD-L1-IN-1 effectively suppressed tumor growth by enhancing the antitumor immune activity of peripheral blood mononuclear cells in co-cultures with PD-L1 expressing cancer cells (PC9 and HCC827 cells). It significantly elevated the release of interferon γ and induced apoptosis in cancer cells, while exhibiting minimal cytotoxicity in healthy cells [1].

C17 Ceramide is a synthetic ceramide that contains a non-natural C17:0 fatty acid acylated to sphingosine. It has been used as a marker of arylsulfatase A and sphingolipid activator B activity in patients undergoing enzyme replacement therapy for the genetic disease metachromatic leukodystrophy.

PD-1-IN-17 TFA is a potent inhibitor of programmed cell death-1 (PD-1), effectively inhibiting 92% of splenocyte proliferation at a concentration of 100 nM.

PD-1 PD-L1-IN-27 is a potent inhibitor of PD-1 PD-L1, with an IC50 of 134 nM, and demonstrates antitumor effects with minimal T cell cytotoxicity. It activates CD8+ T cells and mitigates T cell exhaustion [1].

Josiphos SL-J009-1 Pd G3 has a wide range of applications in life science related research.

PD-1 PD-L1-IN-28, an inhibitor of the PD-1 PD-L1 signaling pathway (IC 50 = 0.744 µM), demonstrates promising research potential in tumor immunity. This immune checkpoint inhibitor effectively blocks the interaction within the pathway, offering insights into cancer treatment strategies.

This synthetic peptide consists of amino acids 1 to 17 of beta amyloid protein. This peptide can be employed in beta amyloid solubility studies.

PD-1/PD-L1-IN 3 TFA inhibits the binding of human PD-1 to PD-Ll with an IC50 of 9 nM.

PD-1-IN-20 [476690-36-9] is the less active enantiomer of PD-1-IN-1 [1346528-06-1].

PD-1 PD-L1-IN-31 is a potent inhibitor of PD-1 PD-L1 (IC50=2.2 nM) that enhances IFN-γ secretion and activates the immune response of peripheral blood mononuclear cells (PBMCs), leading to the inhibition of tumor cells [1].

PD-1 PD-L1-IN-33 (Compound N11), a PD-1 PD-L1 inhibitor with an IC50 of 6.3 nM, effectively impedes the interaction between PD-1 and PD-L1. It enhances T-cell proliferation, activation, and infiltration within tumor environments, thereby exhibiting immunomodulatory and anticancer properties [1].

PD-1 PD-L1-IN-14 (compound 17) is an inhibitor of PD-1 PD-L1 interaction (IC50=27.8 nM) that promotes PD-L1 dimerization, endocytosis, and degradation.

IL-17 Modulator 1 (disodium) is a potent, orally active compound, known for its high efficacy in modulating IL-17. This compound is extensively utilized for researching various diseases such as psoriasis, ankylosing spondylitis, and psoriatic arthritis[1].

PD-1 PD-L1-IN-17 (Compound P20) is a potent PD-1 PD-L1 inhibitor (IC50: 26.8 nM) and a promising lead compound for the development of inhibitors of PD-1 PD-L1 interactions, with potential applications in cancer disease research.

PD-1 PD-L1-IN-26 (Compound II-14) is a potent PD-1 PD-L1 inhibitor with an IC50 of 0.0380 μM. It enhances the immune microenvironment by promoting CD4+ T cell infiltration into tumor tissues, suggesting its potential application in cancer research [1].

PD-1 PD-L1-IN-10 is an orally active PD-1 PD-L1 inhibitor with an IC50 of 2.7 nM, demonstrating potent anticancer efficacy.

PD-1 PD-L1-IN 5 is a potent inhibitor of the PD-1 PD-L1 protein protein interaction (IC50 ≤ 100 nM).

PD-1 PD-L1-IN-22, a small molecule inhibitor (IC50: 0.732 μM), blocks PD-1 PD-L1 protein-protein interactions and can be utilized to study cancer, infectious diseases, and autoimmune diseases.

ACTH (1-17) TFA is a corticotrophin analogue and an effective human melanocortin 1 (MC1) receptor agonist with Ki value of 0.21 nM.

Mcl-1 Inhibitor 17 is a compound that functions as an inhibitor of the Mcl-1 protein, specifically designed for use in cancer and other disease research [1].

PD-1 PD-L1-IN-20 is a small molecule inhibitor of PD-1 PD-L1 protein-protein interaction, blocking the interaction with an IC50 of 5.29 nM. PD-1 PD-L1-IN-20 can be used to study cancer, infectious diseases, and autoimmune diseases.

CYP51 PD-L1-IN-1 (compound L11), a quinazoline with antifungal properties, inhibits CYP51 (IC50: 0.884 μM) and PD-L1 (IC50: 0.083 μM), induces early apoptosis in the fungal cell cycle, decreases intracellular IL-2, NLRP3, and NF-κBp65 protein levels, causes mitochondrial damage and ROS accumulation, leading to fungal lysis and cell death [1].

(3S,8S,9S,10R,13R,14S,17R)-10,13-Dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl (Z)-octadec-9-en-1-yl carbonate is a useful organic compound for research related to life sciences. The catalog number is T65075 and the CAS number is 17110-51-9.

PD-1 PD-L1-IN-23 is a potent, orally active ester prodrug of L7, a benzooxadiazole derivative, that functions as an inhibitor of PD-1 PD-L1. It has undergone biological evaluation for its inhibitory effects on PD-L1, showing significant antitumor effects in both syngeneic tumor models and PD-L1 humanized mice.

PD-1 PD-L1-IN-25, an inhibitor of PD-1 PD-L1 interaction (IC50: 16.17 nM), effectively activates anti-tumor immunity in T cells within PBMCs and can be utilized in cancer research.

PD-1-IN-18 is a PD1 inhibitor of the signaling pathway and functions as an immunomodulator.

PD-1 PD-L1-IN-15 is a potent PD-1 PD-L1 inhibitor (IC50: 60.1 nM) with demonstrated investigational potential for tumor immunotherapy.

PD-1-IN-24 (compound 1) is an orally active PD-1 inhibitor.

Compound 8j, also known as PD-L1 PD-1-IN-1, is a potent inhibitor of the PD-L1 PD-1 interaction, demonstrating an IC50 value of less than 1 nM. It is significant in the field of anti-tumor research [1].

Tunicamycin 17:1 is a mixture of tunicamycin structural isomers that contain a 17-carbon N-acyl chain with variable branching patterns. The N-acyl chain incorporated into tunicamycins, like tunicamycin 17:1, is derived from the same pool of cellular branched-chain fatty acids (BCFAs) inStreptomycesand directly impacts the biological activity of each individual tunicamycin variant.1,2,3Purified tunicamycin 17:1 withisooranteisobranching configurations inhibits bacterial phospho-MurNAc-pentapeptide transferase (MraY) with IC50values of 0.12 and 0.9 μM, respectively.2 1.Price, N.P.J., Jackson, M.A., Hartman, T.M., et al.Branched chain lipid metabolism as a determinant of the N-Acyl variation of Streptomyces natural productsACS Chem. Biol.16(1)116-124(2021) 2.Hering, J., Dunevall, E., Snijder, A., et al.Exploring the active site of the antibacterial target MraY by modified tunicamycinsACS Chem Biol.15(11)2885-2895(2020) 3.Duksin, D., and Mahoney, W.C.Relationship of the structure and biological activity of the natural homologues of tunicamycinJ. Biol. Chem.257(6)3105-3109(1982)

PD-1 PD-L1-IN-34 (Compound (1S,2S)-A25) effectively inhibits the PD-1 PD-L1 interaction (IC50 = 0.029 μM) and demonstrates selective binding affinity to PD-L1 (KD = 0.1554 μM), resulting in the activation of the immune microenvironment and suppression of tumor growth [1].

PD-1 PD-L1-IN-29 (S4-1) is a potent inhibitor of the PD-1 PD-L1 interaction with an IC50 value of 6.1 nM. It effectively binds to PD-L1, promoting its dimerization and internalization, enhancing its localization to the endoplasmic reticulum, and demonstrating anticancer activity.

PD-1/PD-L1-IN-13 is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC50 value of 10.2 nM for PD-1/PD- L1 interaction.PD-1/PD-L1-IN-13 promotes CD8+ T-cell activation and delays tumour growth in a Hepa1-6 homozygous mouse model.

PD-1 PD-L1-IN-16, a potent inhibitor of PD-1 PD-L1 (IC50: 53.2 nM), has demonstrated research potential for tumor immunotherapy.

C17 Globotriaosylceramide is a sphingolipid that has been used as an internal standard for the quantification of globotriaosylceramides in plasma and urine from patients with Fabry disease by GC-MS.

PD-1 PD-L1-IN 5 is an inhibitor of PD-1 PD-L1 protein-protein interaction with an IC50 of ≤100 nM.

PROTAC PD-1 PD-L1 degrader-1, a Cereblon E3 ligand-based compound, is a PD-1 PD-L1 PROTAC that effectively inhibits the PD-1 PD-L1 interaction with an IC50 of 39.2 nM. It restores the suppressed immune response in a co-culture model of Hep3B OS-8 hPD-L1 cells and CD3 T cells and moderately decreases PD-L1 protein levels through a lysosome-dependent mechanism.

ACTH (1-17) TFA, an analogue of adrenocorticotropin, is a potent agonist for the human melanocortin 1 (MC1) receptor with a dissociation constant (K i) of 0.21 nM.

PD-1 PD-L1-IN 6 (compound A13) is a potent inhibitor of PD-1 PD-L1 interaction (IC50 = 132.8 nM) with outstanding immunoregulatory activity. In a Hep3B OS-8 hPD-L1 and CD3 T cell co-culture model, PD-1 PD-L1-IN 6 significantly elevates interferon-γ secretion without significant toxic effects. Additionally, in a T cell-tumor co-culture model, PD-1 PD-L1-IN 6 restores the immune response.

C17 Sphingomyelin, a synthetic derivative of sphingomyelin, is used as an internal standard for the quantification of sphingomyelin.